| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics Inc | Alzheimer Disease; Arthritis, Rheumatoid; Brain Injuries, Traumatic; Colitis, Ulcerative; Diabetes Mellitus, Type 2; Insulin Resistance; Parkinson Disease; Post-Acute COVID-19 Syndrome | Details |
| PN-232 | PN-232; JNJ75105186 | Phase 1 Clinical | Protagonist Therapeutics Inc | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Icotrokinra | PN-235; JNJ-2113; JNJ-77242113-AAC; PN-21235; JNJ-77242113 | Approved | Protagonist Therapeutics Inc | ICOTYDE | United States | Plaque psoriasis | Janssen Biotech Inc | 2026-03-17 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Erythrodermic psoriasis; Generalised pustular psoriasis; Plaque psoriasis; Psoriasis | Details |